Compare · DNA vs RVMD
DNA vs RVMD
Side-by-side comparison of Ginkgo Bioworks Holdings Inc. (DNA) and Revolution Medicines Inc. (RVMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DNA and RVMD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- RVMD is the larger of the two at $40.57B, about 53.6x DNA ($756.6M).
- RVMD has been more active in the news (12 items in the past 4 weeks vs 4 for DNA).
- RVMD has more recent analyst coverage (25 ratings vs 18 for DNA).
- Company
- Ginkgo Bioworks Holdings Inc.
- Revolution Medicines Inc.
- Price
- $10.28-12.44%
- $178.07-5.91%
- Market cap
- $756.6M
- $40.57B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- 2020
- News (4w)
- 4
- 12
- Recent ratings
- 18
- 25
Ginkgo Bioworks Holdings Inc.
Ginkgo Bioworks Holdings, Inc. develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is based in Boston, Massachusetts.
Revolution Medicines Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. The company was incorporated in 2014 and is headquartered in Redwood City, California.
Latest DNA
- Ginkgo Bioworks to Provide Autonomous Lab Access to NSF X-Labs Researchers, Contributing Cloud Lab Time and Protein Testing Services to $1.5 Billion Breakthrough Science Program
- Araceli Biosciences and Ginkgo Bioworks Bring Cellular Imaging at Scale to Nebula's Lab-in-the-Loop
- SEC Form 4 filed by Ginkgo Bioworks Holdings Inc.
- Ginkgo Datapoints and Apheris Welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium
- Director Henry Christian O sold $35,405 worth of shares (5,000 units at $7.08), decreasing direct ownership by 21% to 19,310 units (SEC Form 4)
- Ginkgo Datapoints Announces Partnership with TuneLab to Close the Gap between AI Models and Lab Data
- SEC Form 144 filed by Ginkgo Bioworks Holdings Inc.
- Ginkgo Bioworks Joins ARPA-H GIVE Program to Build Autonomous Manufacturing System for Individualized RNA Medicines
- Officer Coen Steven P. converted options into 743 shares and sold $2,302 worth of shares (330 units at $6.98), increasing direct ownership by 0.80% to 51,851 units (SEC Form 4) (tax liability)
- Ginkgo Bioworks downgraded by TD Cowen with a new price target
Latest RVMD
- William Blair initiated coverage on Revolution Medicines
- Revolution Medicines’ RASONQUE(™) (daraxonrasib) Receives Positive CHMP Opinion Recommending Marketing Authorization in European Union for Metastatic Pancreatic Cancer
- Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda
- SEC Form 8-K filed by Revolution Medicines Inc.
- Revolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUE™ (daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic RAS G12D Pancreatic Cancer
- Chief Development Officer Sandler Alan B. exercised 6,000 shares at a strike of $58.84 and sold $1,275,294 worth of shares (6,309 units at $202.14) as part of a pre-agreed trading plan, decreasing direct ownership by 0.58% to 52,559 units (SEC Form 4)
- SVP & General Counsel Cislini Jeff sold $158,600 worth of shares (765 units at $207.32) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 51,776 units (SEC Form 4)
- Officer Mancini Anthony sold $743,285 worth of shares (3,708 units at $200.45) as part of a pre-agreed trading plan and exercised 3,121 shares at a strike of $33.62, decreasing direct ownership by 1% to 39,765 units (SEC Form 4)
- KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034
- Director Anderson Elizabeth M exercised 5,070 shares at a strike of $1.12 and sold $1,958,016 worth of shares (10,143 units at $193.04) as part of a pre-agreed trading plan, decreasing direct ownership by 54% to 4,333 units (SEC Form 4)